NCT05785039 trial: what clinicians have said so far
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
- NCT05785039 ↗
- Recruiting
- Sichuan Baili Pharmaceutical Co., Ltd.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05785039 (izalontamab brengitecan (BL-B01D1) in locally advanced or metastatic solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05785039 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- Phase IIa/IIb Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-B01D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Urinary System Tumor; Solid Tumor
- Interventions
- BL-B01D1
- Arms
- Study treatment · Experimental
- Enrollment
- 76 (estimated)
- Primary outcomes
- Phase IIa: Recommended Phase II Dose (RP2D)
- Phase IIb: Objective response rate (ORR)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. with Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Start
- Apr 20, 2023
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05785039 · updated Aug 27, 2026